Chatel-Guyon, France

Andre J Monteil


Average Co-Inventor Count = 3.8

ph-index = 5

Forward Citations = 77(Granted Patents)


Location History:

  • 63400 Chamalieres, FR (1976)
  • Gerzat, FR (1976 - 1978)
  • Chatel-Guyon, FR (1977 - 1993)

Company Filing History:


Years Active: 1976-1993

Loading Chart...
18 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andre J Monteil

Introduction

Andre J Monteil is a notable inventor based in Chatel-Guyon, France. He has made significant contributions to the field of pharmaceuticals, particularly in the development of neuroleptic and antidepressant compounds. With a total of 18 patents to his name, Monteil's work has had a considerable impact on medicinal chemistry.

Latest Patents

Monteil's latest patents include innovative compounds such as 4-[4- or 6-(trifluoromethyl-2-pyridinyl)]-1-piperazinylalkyl substituted lactam derivatives. This invention relates to neuroleptic and antidepressant compounds that exhibit a specific structural formula. Another significant patent involves pyridinylpiperazine derivatives, which display improved preferential serotonin-1A binding activity. These compounds are designed to enhance therapeutic efficacy in treating various mental health conditions.

Career Highlights

Throughout his career, Monteil has worked with esteemed organizations such as the Centre Européen de Recherches Mauvernay. His research has focused on developing novel pharmaceutical agents that address critical health issues. His dedication to innovation in the field has earned him recognition among his peers.

Collaborations

Monteil has collaborated with notable individuals in the industry, including Jacques A Simond and Jacques Moleyre. These partnerships have contributed to the advancement of his research and the successful development of his patented compounds.

Conclusion

Andre J Monteil's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a leading inventor. His work continues to influence the development of new therapeutic agents that can improve patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…